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The epidermal growth factor receptor (EGFR) pathway is a therapeutic target in the management of colorectal cancer (CRC).
EGFR antagonists are active in this disease; however, only a subset of patients respond to such therapy. A Kirsten ras sarcoma
viral oncogene (KRAS) wild-type (WT) status of the tumor is necessary, but possibly not suﬃcient, for a response to anti-EGFR
monoclonal antibody therapy. Mechanisms of primary resistance to such therapy in patients harboring KRAS WT tumors are
discussed. Strategies to overcomeresistance to anti-EGFR monoclonalantibody therapy, includingnovel agents and combinations
of novel therapies, are explored. Also, the use of anti-EGFR monoclonal antibodies in the adjuvant and neoadjuvant setting is
reviewed.
1.Introduction
Tumor growth and progression depends in part on the
activity of cell surface membrane receptors which control
signal transduction pathways. These growth factor receptors
c a nh a v ea b e r r a t i o n si nt h e i re x p r e s s i o na n dr e g u l a t i o na n d
activation of growth factor pathways is common in many
malignancies [1]. The EGFR, a transmembrane glycoprotein
also called ERBB-1 or HER1, is a member of a family of
receptor tyrosine kinases (TKs). The EGFR is involved in
signaling pathways controlling cell growth, diﬀerentiation,
and proliferation and is expressed in many diﬀerent types
of normal tissues as well as several tumor types, including
CRC [2, 3]. Figure 1 illustrates the main EGFR signaling
pathways described [4]. When a ligand binds to the EGFR,
the receptor forms a dimer resulting in a signaling cascade
within the cell via tyrosine kinase activity [5]. This signaling
cascade occurs by the activation of receptor autophospho-
rylation which triggers a number of intracellular pathways
regulating cell proliferation, prevention of apoptosis, and
promotion of invasion, metastasis, and neovascularization
[6]. The proto-oncogene c-erb-B encodes the EGFR, and
activation of the proto-oncogene results in EGFR expression
in many tumors [7, 8]. There was therefore interest in
investigating this pathway as a potential anticancer therapy
target.
Pharmacologically, there are two classes of EGFR antag-
onists currently in clinical use: antiEGFR monoclonal anti-
bodiesdirected against theextracellular domainoftherecep-
torandoralsmall-molecule EGFRTKinhibitorswhich block
the receptor TK activity competitively [10]. The antiEGFR
monoclonalantibodies,cetuximabandpanitumumab,actby
binding tothe extracellular region of theEGFR and therefore
block the ligand-binding region which prevents ligand-
induced TK activation [11]. These monoclonal antibodies
solely recognize the EGFR, making them very selective for
their target [5]. The small-molecule EGFR TK inhibitors,
erlotinib and geﬁtinib, inhibit the catalytic activity of the
TK by competing with adenosine triphosphate (ATP) to
bind to the intracellular domain [10]. These small-molecule
inhibitors are not exclusive to the EGFR pathway and
can block diﬀerent receptor tyrosine kinases, such as the
vascular endothelial growth factor (VEGF) receptor and
other members of the EGFR family.2 Pathology Research International
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Figure 1: EGFR signalingpathway [4]. (Reprinted with permission
from American Society of Clinical Oncology 2008. All rights
reserved.)
Anti-EGFR monoclonal antibodies have been evaluated
in both untreated metastatic CRC and chemotherapy refrac-
tory disease. Figure 2 summarizes the current treatment
paradigm for metastatic colorectal cancer including the
appropriate incorporation of antiEGFR monoclonal anti-
body therapy which improves survival for appropriately
selected patients [9]. Table 1 summarizes selected clinical
trialsofantiEGFRmonoclonalantibodiesinmetastaticCRC.
Response rates with single-agent antiEGFR monoclonal
antibodies range from 9–12%, with much higher response
rates observed when cetuximab is used in combination with
chemotherapy [12–22]. When administered to unselected
metastatic CRC patients, only a minority responded to
EGFR inhibitor therapy. Therefore, a method to identify and
predict sensitivity to these drugs was needed.
2.Predictionof Responseto
Anti-EGFRMonoclonal Antibodies
The RAS family of proto-oncogenes include HRAS, KRAS,
and NRAS [23]. KRAS (Kirsten ras sarcoma viral onco-
gene) is a guanosine triphosphate-(GTP-) binding protein
downstream of the EGFR and is a central component of
the mitogen-activated protein kinase (MAPK) pathway, a
component of the EGFR signaling cascade [23]. Roughly
40% of colorectal cancers are characterized by a mutation
in the KRAS gene [24]. About 90% of these mutations
occur in codons 12 and 13 in exon 2 of the KRAS gene,
with the remaining mutations occurring in codons 61 and
146 (roughly 5% each) [25, 26]. Such KRAS mutations
lead to EGFR-independent constitutive activation of the
signaling pathway and predict for a lack of response and
beneﬁt from antiEGFR monoclonal antibodies cetuximab
and panitumumab [27–35]. De Roock et al. showed that
codon 61 mutations predicted for lack of response to
cetuximab similar to codon 12 and 13 mutations; however,
codon 146 mutations did not aﬀect cetuximab eﬃcacy
[26]. Failure to test for codon 61 mutations may miss
a signiﬁcant mutation which would confer resistance to
antiEGFR monoclonal antibody therapy. There is a very
high concordance of KRAS mutational status between the
primary tumor and metastasis, ranging from 92–100% [36–
38]. However, KRAS mutation status heterogeneity between
primary tumors, lymph nodes and distant metastases in 5–
10% of patients has been reported, with mixed responses
to antiEGFR monoclonal antibody therapy in those with
metastatic CRC [37, 39, 40]. Because of this, some clinicians
have called for a reassessment of KRAS mutation status on
metastatic foci in situations where only the primary tumor
was assessed for KRAS status [41].
Table 2 summarizes clinical trials of antiEGFR mon-
oclonal antibodies which included analysis of treatment
eﬀect and KRAS mutation status. Amado et al. assessed the
predictive role of KRAS mutational status in a randomized
phase III trial comparing panitumumab monotherapy with
best supportive care (BSC) in patients with chemotherapy
refractory metastatic CRC [24]. This trial showed that the
clinical beneﬁt associated with panitumumab was restricted
to the KRAS WT population. KRAS mutations predicted
for lack of clinical beneﬁt to panitumumab [24]. Similarly,
Karapetis et al. showed that treatment with cetuximab
signiﬁcantly improved OS and PFS in patients with KRAS
WT tumors; however, in this chemotherapy-resistant patient
population, those with mutated KRAS tumors did not
beneﬁt [38]. Use of cetuximab as ﬁrst-line treatment for
metastatic disease was investigated by Van Cutsem et al.;
patients were randomly assigned to receive FOLFIRI with or
without cetuximab [36]. A statistically signiﬁcant beneﬁt in
PFS for patients with KRAS WT tumors receiving cetuximab
and chemotherapy was conﬁrmed in a ﬁnal presentation
of this trial [42]. Bokemeyer et al. investigated the use
of cetuximab in combination with FOLFOX chemother-
apy as initial treatment for metastatic disease [34]. A
retrospective analysis of this data revealed that cetuximab
and chemotherapy had a statistically signiﬁcant increased
response rate and lower risk of disease progression compared
with chemotherapy alone in patients with KRASWT tumors
[43].Prospectively, panitumumab hasbeeninvestigated with
either FOLFOX or FOLFIRI chemotherapy in the ﬁrst-line
metastatic setting [44, 45]. The addition of panitumumab
to FOLFOX chemotherapy was associated with a statistically
signiﬁcant improvement in PFS [44]. Taken together, the
data in Table 2 supports that in metastatic CRC, KRAS
WT and mutation status predict for potential sensitivity
to, and deﬁnite resistance to, respectively, both antiEGFR
monoclonal antibodies, regardless of prior treatment and
irrespective of use as monotherapy or in combination.
Notably, while KRAS status is an established predictor of
response to antiEGFR monoclonal antibody therapy, it has
been disproven as a prognostic marker. In contrast to KRAS
mutational status, evaluation of EGFR expression of CRC
cells has failed to demonstrate predictive value for antiEGFR
monoclonal antibody therapy. Cunningham et al. reported
that theintensity of EGFR staining byimmunohistochemical
analysis did not correlate with response rate to cetuximab
[13]. Similar data has also been reported with panitumumab
[46]. KRAS mutated CRC absent of antiEGFR monoclonalPathology Research International 3
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Figure 2: The current treatment paradigm for patients with metastatic colorectal cancer who are appropriate for intensive therapy [9]. ∗For
patients with KRAS WT gene only. CapeOX: capecitabine + oxaliplatin.
antibody therapy is not inferior to patients with KRAS
WT disease. The evaluation of KRAS mutational status is a
mandatory aspect of management of patients at the time of
diagnosis of metastatic CRC.
3.Mechanisms of Resistance
While KRAS mutations are a major mechanism of primary
resistance to antiEGFR monoclonal antibody therapies,
resistance mechanisms in KRAS WT patients are also being
deﬁned. Forty-sixty percent of patients with KRAS WT
tumors fail to respond to treatment with antiEGFR mono-
clonal antibodies [51]. Therefore, other possible molecular
determinants of response are being identiﬁed in those
patients with EGFR monoclonal antibody-resistant WT
KRAS disease.
The importance and frequency of NRAS (a ras onco-
gene variant) mutations in CRC remains under-investigated
[52, 53]. Lambrechts et al. found that NRAS, KRAS, and
BRAF mutations were all mutually exclusive events, with
combined WT status of these genes associated with higher
response rates and longer progression-free survival times
[54]. Lambrechts et al. also reported that an NRASmutation
was associated with a lack of response to cetuximab. Irahara
et al. investigated the relationship between NRAS mutations
and clinical outcome in a collection of 225 colorectal cancers
from two prospective cohort studies [55]. NRAS mutations
were detected in 2.2% of the CRCs. There was no apparent
association between the NRAS mutations and any clinical or
pathologic features, including patient survival. However, the
low frequency of NRAS mutations may obscure a signiﬁcant
relation. De Roock et al. conducted a retrospective analysis
of over 700 tumor samples from patients treated with
cetuximab plus chemotherapy and found a NRAS mutation
frequency of2.6%.Additionally, inKRASwild types, carriers
of NRAS mutations had a signiﬁcantly lower response rate
to cetuximab than NRAS wild types (7.7% versus 38.1%,
P = .013) [26]. There was, however, no signiﬁcant diﬀerence
in median PFS (14 versus 26 weeks, P = .055) and median
OS (38 versus 50 weeks, P = .051) between NRAS wild types
and mutants [26].
B-type Raf kinase (BRAF) is a component of the RAS-
RAF-MEK signaling cascade of the EGFR (see Figure 1)[ 56].
A speciﬁc mutation in the BRAF gene (V600E) is present in
approximately 5–8% of CRCsand is thought to be limited to
those tumors without mutations in exon 2 of KRAS[42, 57].
BRAF, which is located directly downstream from RAS, can
have activating mutations leading to stimulation of the MEK
pathway [56, 58]. BRAF mutations appear to confer a poor
prognosis, and it appears that BRAF mutations also predict
for a lack of response to antiEGFR monoclonal antibodies
[42, 57, 59, 60]. Loupakis et al. analyzed 87 patients with
KRAS WT tumors for the BRAF V600E mutation who were
receiving irinotecan and cetuximab for refractory metastatic4 Pathology Research International
Table 1: Clinical trials of antiEGFR monoclonalantibodies in metastatic CRC.
Study Setting Treatment No. of patients ORR (%) mTTP (mos) mPFS (mos) mOS (mos)
Single Arm
phase II [12]
Irinotecan-
refractory
Cetuximab
monotherapy 57 9 1.4 N.R. 6.4
Randomized
phase II [13]
Refractory
disease to 5-FU
and Irinotecan
Cetuximab
monotherapy
vs. Cetuximab +
Irinotecan
111 vs. 218 10.8∗ vs. 22.9 1.5∗ vs. 4.1 N.R. 6.9 vs. 8.6
Single Arm
phase II [14]
Refractory
disease to 5-FU,
Irinotecan, and
Oxaliplatin
Cetuximab
monotherapy 346 12.4 1.4 N.R. 6.6
Single Arm
phase II [15]
First-line
treatment
Cetuximab +
Irinotecan +
5-FU/FA
21 67 9.9 N.R. 33.0
Randomized
phase III [16]
Refractory
disease to 5-FU,
Irinotecan and
Oxaliplatin
Cetuximab
monotherapy
vs. BSC
287 vs. 285 8∗ vs. 0 N.R. 1.9∗ vs. 1.8 6.1∗ vs. 4.6
Single Arm
phase II [17]
First-line
treatment
Cetuximab +
FOLFOX-4 43 72 N.R. 12.3 30
Randomized
phase III [18]
Refractory to
Oxaliplatin
Cetuximab +
Irinotecan vs.
Irinotecan
648 vs. 650 16.4∗ vs. 4.2 N.R. 4.0∗ vs. 2.6 10.7 vs. 10.0
Randomized
phase III [19]
First-line
treatment
Cetuximab +
FOLFIRI vs.
FOLFIRI
602 vs. 600 46.9∗ vs. 38.7 N.R. 8.9∗ vs. 8.0 N.R.
Randomized
phase III [20]
Refractory
disease to 5-FU,
Irinotecan and
Oxaliplatin
Panitumumab
monotherapy
versus BSC
231 vs. 232 10.0∗ vs. 0 N.R. 8 weeks∗ vs. 7.3
weeks 6.5 vs. 6.5
Randomized
phase II [21]
Refractory to
Irinotecan
Irinotecan +
Cetuximab+
Bevacizumab vs.
Cetuximab +
Bevacizumab
43 vs. 40 37 vs. 20 7.3 vs. 4.9 N.R. 14.5 vs. 11.4
Single Arm
phase II [22]
Refractory to
Irinotecan +
Bevacizumab
Cetuximab +
Bevacizumab +
Irinotecan
33 9 3.9 N.R. 10.6
∗Statisticallysigniﬁcant improvement.
ORR: overall response rate; mTTP: median time to progression; mPFS: median progression-free survival; mOS: median overall survival; N.R.: not reported;
5-FU: 5-ﬂuorouracil; BSC: best supportive care; FA: folinic acid; NS: not signiﬁcant.
CRC. This mutation was found in 15% of the patients
and was associated with a lack of response to therapy (0%
versus 32%, P = .016) and a shorter overall survival (4.1
months versus 13.9 months, P = .037) [61]. An additional
retrospective analysis of 113 patients treated with antiEGFR
monoclonal antibodies found the V600E BRAF mutation
in 14% of the KRAS WT patients and was associated with
no response to therapy and a statistically signiﬁcant shorter
progression-free survival and overall survival compared with
BRAF WT patients [59]. In De Roock’sretrospective analysis
of tumor samples from patients treated with cetuximab plus
chemotherapy, a BRAF mutation was discovered in 4.7% of
tumors[26].InKRASwildtypes,carriersofBRAFmutations
had a signiﬁcantly lower response rate to cetuximab than
in BRAF wild types (8.3% versus 38.0%, P = .0012), a
signiﬁcantly shorter PFS (8 versus 26 weeks, P<. 0001),
and a signiﬁcantly shorter OS (26 versus 54 weeks, P<
.0001) [26]. KRAS and BRAF mutation status do not,
however, appear to aﬀect the clinical beneﬁt of oxaliplatin or
irinotecan onPFSorOS[62].Severalcompounds(PLX4032,
PLX4720, and GDC-0879) which selectively inhibit the
kinase enzyme BRAF containing the V600E mutation are in
clinical development [63]. In BRAF mutant cancer cell lines,
these selective BRAF inhibitors potently block RAF-MEK-
ERK signaling. However, in those tumors that are BRAFWT,
butpossess a KRAS mutation, these BRAFinhibitors activate
this same pathway and therefore should be avoided in those
cancers with RAS mutations [64–66].Pathology Research International 5
Table 2: Clinical trials with retrospective subset analyses of antiEGFR eﬃcacy in relation to KRAS mutation status.
Study Setting Treatment KRAS genotype No. of patients ORR (%) mPFS (mos) mOS (mos)
Single arm studies
Li` evre et al. [34] Second-line
treatment Cetuximab WT
Mut
65
24
40∗
0
31.4wk∗
10.1
14.3∗
10.1
De Roock et al. [29] Irinotecan
refractory
Cetuximab or
cetuximab +
irinotecan
WT
Mut
57
46
41†
0
34wk† (combo)
12 (cetux)
12
44.7wk† (combo)
27wk (cetux)
25.3–27.3
Khambata-Ford
et al. [28]
Second or
third-line
treatment
Cetuximab WT
Mut
50
30
10
0 N.R. N.R.
Di Fiore et al. [47] Refractory
disease
Cetuximab +
chemotherapy
WT
Mut
43
16
20.3
0 N.R. N.R.
Benvenuti et al. [48] Various lines
of treatment
Cetuximab or
panitumumab
or cetuximab +
chemotherapy
WT
Mut
32
16
31
6 N.R. N.R.
Randomized studies
Amado et al. [24] Refractory
disease
Panitumumab +
BSC vs. BSC
WT
Mut vs.
WT
Mut
124
84
119
100
17
0
0
0
12.3wk∗
7.4wk
7.3wk
7.3wk
8.1
4.9
7.6
4.4
Van Cutsem et al. [33] First-line
treatment
FOLFIRI +
cetuximab vs.
FOLFIRI
WT
Mut vs.
WT
Mut
172
105
176
87
59.3
36.2
43.2
40.2
9.9∗
7.6
8.7
8.1
24.9
17.5
21.0
17.7
Van Cutsem et al. [42] First-line
treatment
FOLFIRI +
cetuximab vs.
FOLFIRI
WT
Mut vs.
WT
Mut
316
214
350
183
57.3∗
31.3
39.7
36.1
9.9∗
7.4
8.4
7.7
23.5∗
16.2
20.0
16.7
Bokemeyer et al. [31] First-line
treatment
FOLFOX +
cetuximab vs.
FOLFOX
WT
Mut vs.
WT
Mut
61
52
73
47
61∗
33
37
49
7.7∗
5.5
7.2
8.6
N.R.
Bokemeyer et al. [43] First-line
treatment
FOLFOX +
cetuximab vs.
FOLFOX
WT
Mut vs.
WT
Mut
82
77
97
59
57∗
34
34
53
8.3∗
5.5
7.2
8.6
22.8
18.5
13.4
17.5
Karapetis et al. [35] Refractory
disease
Cetuximab +
BSC vs. BSC
WT
Mut vs.
WT
Mut
115
81
113
83
12.8
1.2
0
0
3.7∗
1.8
1.9
1.8
9.5∗
4.5
4.8
4.6
Siena et al. [44] First-line
treatment
FOLFOX +
panitumumab
vs. FOLFOX
WT = 656
Mut = 440
55
48
9.6 (wt)∗
7.3 (mut)
8.0 (wt)
8.8 (mut)
N.R.
Kohne et al. [45] First-line
treatment
FOLFIRI +
panitumumab
WT
Mut
85
57
48
29 N.R. N.R.6 Pathology Research International
Table 2: Continued.
Study Setting Treatment KRAS genotype No. of patients ORR (%) mPFS (mos) mOS (mos)
Tol et al. [49] First-line
treatment
CAPOX +
bevacizumab +
cetuximab vs.
CAPOX +
bevacizumab
WT
Mut
WT
Mut
158
98
156
108
50.0
59.2
61.4∗
45.9
10.5∗
8.1
10.6
12.5
21.8
17.2
22.4
24.9
H e c h te ta l .[ 50] First-line
treatment
FOLFOX +
bevacizumab +
panitumumab
vs. FOLFOX +
bevacizumab
WT
Mut
WT
Mut
201
135
203
125
50
47
56
44
9.8
10.4
11.5
11.0
20.7
19.3
24.5
19.3
∗Statisticallysigniﬁcant improvement
†Statisticallysigniﬁcant improvement for the combination of cetuximab and irinotecan only.
ORR: overall response rate; mPFS: median progression-free survival; mOS: median overall survival; N.R.: not reported; BSC: best supportive care.
The mitogen-activated protein kinase kinase (MEK, also
known as MAP2K)is downstream ofBRAFin the RAS-RAF-
MEK signaling cascade of the EGFR and uses extracellular
signal-regulated kinase (ERK) as a substrate (see Figure 1)
[67]. A number of MEK inhibitors such as AS703026,
AZD6244 and RO5068760 have been or currently are being
investigated in phase 1 and 2 clinical trials [68, 69]. The
development of several MEK inhibitors has been halted
because of either very low response rates or due to ocular
toxicity [70]. These agents have however shown substantial
preclinical activity in tumor cell lines harboring the BRAF
V600E gene mutation [71]. It has been established that
KRAS has a number of downstream eﬀectors that are not
blocked by MEK inhibition, and indeed BRAF mutant cell
lines were found to be more sensitive to MEK inhibitors
than KRAS mutant cells [71]. It is imperative to be able
to identify which patients are likely to respond to MEK
inhibitors, and it appears that those with BRAF mutations
are a good start. Given that KRAS signaling operates
throughanumberofdownstream eﬀectors,thosewithKRAS
mutations may require a combination of targeted agents.
Preclinical evidencesuggests that BRAFgene ampliﬁcation is
amechanism of resistance to bothMEK and BRAFinhibitors
and a combination of these inhibitors may be a strategy to
overcome this [72].
An additional EGFR pathway is the PTEN/PI3K/AKT
pathway [phosphatase and tensin homologue gene
(PTEN)]. PTEN encodes a phosphatase which uses
phosphatidylinositol-3,4,5-triphosphate (PIP-3) as a major
substrate [73].LossofPTEN function leadstoincreased PIP-
3 concentration, with resultant AKT hyperphosphorylation
protecting tumor cells from apoptosis [73]. Roughly 60%
of primary CRCs have a hyperphosphorylated AKT [74].
PTEN loss, activating mutations of phosphatidylinositol 3-
kinase catalytic alpha polypeptide (PIK3CA) and activating
mutations in KRAS/BRAF/MAPK confer resistance to
apoptosis induced by cetuximab [75]. In patients with
KRAS WT tumors treated with a cetuximab-based regimen,
PTEN loss was associated with a signiﬁcantly shorter OS
[60]. Approximately one third of CRCs harbor activating
somatic mutations in PIK3CA, and it has been reported
that these mutations are predictive of lack of beneﬁt from
antiEGFR therapy [76]. Additional genetic alterations which
could confer resistance to antiEGFR monoclonal antibodies
include an inhibitor of PI3K signaling; coampliﬁcation of
PAK4 (p-21-activated protein kinase) and AKT, which are
downstream mediators of PI3K signaling; and ampliﬁcation
of IRS2 (insulin receptor substrate 2), which is an upstream
activator of PI3K signaling [77, 78].
4. Strategiesto Overcome Resistance
A number of approaches to the problem of resistance to
antiEGFR monoclonal antibody therapy have been stud-
ied and are ongoing. Combining antiEGFR monoclonal
antibodies with cytotoxic chemotherapy has already been
discussed. Erlotinib and geﬁtinib, two oral small molecule
EGFR inhibitors, are inactive by themselves [79, 80]. The
combinationoferlotinibwith capecitabineandoxaliplatinin
previously treated patients and the combination of geﬁtinib
with FOLFOX were investigated in small phase II studies
with favorable results, however randomized trials with
chemotherapy alone as a control are needed [81–83]. Dual
antiEGFR therapy with antiEGFR monoclonal antibodies
plus antiEGFR TK inhibitors may overcome resistance to
either drug alone. A 41% response rate was reported for
the combination of cetuximab and erlotinib in patients with
refractory disease, however this was limited to patients with
KRAS and BRAF WT tumors [84].
EGFR and vascular endothelial growth factor (VEGF)
have several signal transduction pathways in common, with
preclinical data revealing that antiEGFR and antiVEGF drug
combinations have synergistic activity [85]. The BOND-2
study randomized patients with irinotecan- and oxaliplatin-
refractory but bevacizumab na¨ ıve disease to cetuximab and
bevacizumab with or without irinotecan [21]. Response
rates, TTP and OS favored the triple drug regimen, however,
these results did not hold up in a subsequent study of
this combination [21, 22]. Two subsequent randomized
phase III trials have shown that combinations of antiEGFRPathology Research International 7
monoclonal antibodies plus bevacizumab do not improve
outcomes and can actually cause increased toxicity irrespec-
tive of KRAS mutational status. The PACCE trial evaluated
panitumumab combined with oxaliplatin- or irinotecan-
based chemotherapy plus bevacizumab. The dual mono-
clonal antibody arm was associated with increased toxicity
and signiﬁcantly shorter PFS in patients with both KRAS
WT and mutant tumors [50]. Similar results were observed
with the combination of cetuximab to a regimen containing
capecitabine, oxaliplatin, and bevacizumab in the CAIRO2
trial [49].
Novel agents and combinations are being employed in
an attempt to overcome antiEGFR monoclonal antibody
resistance. Motesanib, an oral inhibitor of VEGF, platelet
derived growth factor (PDFG) and Kit receptors is being
investigated with or without panitumumab in patients with
refractory disease [86]. A number of inhibitors of the
mutantBRAFkinaseareinclinicaldevelopment,asdiscussed
above [87]. AMG 102 is an investigational monoclonal
antibody against human hepatocyte growth factor (also
known as cMET, of which overexpression correlates with
cetuximab resistance) is being studied in combination with
panitumumab in patients with metastatic CRC [88, 89].
5.Neoadjuvant and AdjuvantTherapy
Given the clinical beneﬁt of antiEGFR monoclonal anti-
bodies in patients with metastatic disease, evaluation
of these therapies as postoperative (adjuvant) treatment
was warranted. In the adjuvant setting, eradication of
micrometastatic disease is associated with increased cure
rates. N0147 randomized 1760 patients with resected stage
III KRAS WT colon cancer to FOLFOX with or without
cetuximab [90]. Interim analysis led to premature closure of
this trial after it was determined that no group of patients
beneﬁted from cetuximab [90]. Initially this trial enrolled
patients regardless of KRAS mutational status, and among
658 patients with mutant KRAS, the addition of cetuximab
to FOLFOX resulted in impaired disease-free survival (DFS)
and a trend toward impaired OS [91].
In patients with rectal cancer, EGFR is a logical tar-
get in combination with neoadjuvant radiotherapy (RT).
Retrospective analyses have demonstrated lower pathologic
complete response (pCR) rates and shorter DFS in patients
with rectal cancer expressing EGFR who were treated with
neoadjuvant RT, suggesting that radiosensitivity might be
increased by targeting the EGFR [92, 93]. Several phase I/II
studies have investigated the combinations of cetuximab and
chemoradiotherapy in the neoadjuvant setting for patients
with rectal cancer. These studies have demonstrated that
cetuximab could be safely combined with preoperative
chemoradiotherapy but the pCR rates have been low (5–
12%) [94–100]. In two of these studies [96, 99], subsequent
analyses were done to correlate KRAS mutation status with
response rate. Among patients with KRAS WT tumors,
Bengala et al. reported a trend toward a greater rate of
tumorregression(36.7%forKRASWTversus11%forKRAS
mutant), however it did not reach statistical signiﬁcance
(P = .12) [101]. Debucquoy et al. also did not ﬁnd
a correlation between KRAS WT tumors and pathologic
response to therapy [102]. To our knowledge, panitumumab
has not been studied in combination with RT in patients
with rectal cancer.Given thefailure ofantiEGFR monoclonal
antibodies to demonstrate a beneﬁt in the adjuvant setting
for stage III WT KRAS colon cancer, the value of further
study of these agents for rectal cancer is doubtful.
Preclinically geﬁtinib has demonstrated improved
radiosensitization [103]. Valentini et al. investigated the
combination of geﬁtinib, continuous infusion 5-ﬂuorouracil
(5-FU) and pelvic RT in 41 patients with locally advanced
rectal cancer and reported a pCR rate of 30%, however
toxicity was an issue and further studies are necessary to
establish the safety of this combination [104].
The eﬀect of combined antiEGFR and antiVEGF therapy
in combination with preoperative chemoradiotherapy for
rectal cancer remains unknown, however given the negative
results reported for combined EGFR and VEGF blockade
in patients with metastatic CRC in combination with
chemotherapy, studies investigating this avenue are unlikely
[22, 49, 50]. Blaszkowsky et al. performed a small study
investigating the combination of bevacizumab, erlotinib and
5-FU with RT in patients with locally advanced rectal cancer
[105].Theregimen wasfoundtobewell-toleratedandhighly
active with a pCR rate of 47% and may deserve further
investigation. However, the value of pCR as a surrogate for
DFS and OS is uncertain.
6.Conclusion
Anti-EGFR monoclonal antibodies are among the standard
treatment options for patients with metastatic CRC given
their established eﬃcacy. It is now clear that the beneﬁt
of antiEGFR monoclonal antibodies is isolated to patients
with KRAS WT tumors. It appears that KRAS mutational
status is just the beginning of our understanding of the
EGFR as an integral component of the biology of CRC.
Given that only a subset of patients respond to antiEGFR
therapy, there is a need for better predictors to guide patient
selection for such therapy. Several important components of
the EGFR signaling pathway have been discovered, including
BRAF, PTEN, AKT and PI3K, which deserve further study
as predictors of response to existing treatments, or as targets
of new interventions. The unexpected detrimental outcome
associated with combined EGFR and VEGF blockade is a
reminder of how much there is still to learn. New combina-
tions and novel agents will continue to shed light on how
to overcome resistance to inhibitors of the EGFR pathway,
and hopefully new targets will be identiﬁed. Further study of
howtoemployourknowledgeofEGFRpathwayinhibitorsto
improveoutcomesintheadjuvantand neoadjuvant settingis
also warranted.
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